The role of high blood pressure at admission has been studied in selected patient populations with a history of hypertension and supratentorial-but not infratentorial-hemorrhage. 7, 9 The authors of these studies have reported impaired outcome after ICH in patients with a high MABP at admission. However, the confounding roles of age, stroke severity, and location have not been thoroughly investigated. Likewise, the role of admission hyperglycemia in patients with ICH has been poorly investigated, and the results are conflicting. In their review, Capes et al. 5 reported no association between admission hyperglycemia and the 1-month death rate in 4 studies, whereas the authors of 2 recent studies found admission hyperglycemia to be associated with poor outcome in both diabetic and nondiabetic patients. 10, 21 The authors of 2 studies reported diabetes to be an independent predictor of early death in patients with ICH. 1, 21 The aim of the present study was to estimate the impact of hypertension and diabetes as well as admission MABP and hyperglycemia on short-term survival in paHypertension and diabetes as predictors of early death after spontaneous intracerebral hemorrhage Clinical article tients with spontaneous ICH. We analyzed the effects of several factors on survival to discover which independent predictors were truly relevant and which reflected only a stress response to the severity of bleeding.
Methods

Patient Population
All patients with spontaneous ICH who were admitted to the Stroke Unit of the Department of Neurology, Oulu University Hospital, Finland, between January 1993 and January 2004 were included in this study. Our institution is the only hospital that serves patients with acute stroke in Northern Ostrobothnia (population 373,868 as of December 31, 2003). We excluded patients who were not residents in the hospital's catchment area, those with bleeding caused by brain tumors, aneurysms, vascular malformations, hematological malignancies, coagulation disorders, or head traumas, and those in need of immediate surgery. Altogether 453 patients with ICH were admitted during the study period. Most patients (94.2%) were admitted within 48 hours of the first symptoms of ICH. Admission plasma glucose values and blood pressure levels were available in 379 patients; 74 patients who lacked this information were excluded from the study. In addition, 89 patients who required immediate surgery were also excluded. The ethics committee of our institution approved the study protocol.
Neuroradiological Methods
Intracerebral hemorrhage was verified on CT scans in all cases, and secondary structural abnormalities were sought on follow-up images (CT or MR imaging) obtained 2-3 months after the hemorrhage. Angiography was performed if aneurysmal bleeding was suspected. All CT scans were examined and the locations and volumes of hematomas measured by an experienced neuroradiologist (J.P.) blinded to the patients' case histories. The hematomas were divided into categories based on location. Hematoma volumes were measured on a workstation using the method previously described, 2 and the presence of IVH was recorded.
Medical Records
Data were collected retrospectively from patient medical records. The following information was collected: time of ICH onset (as defined by acute onset of headache or neurological deficit), previous diseases, medications, and health habits such as current cigarette smoking status and recent heavy drinking. Admission plasma glucose levels and blood pressure values were obtained during transportation to the hospital or in the emergency department. Patients were considered hypertensive if their blood pressure readings prior to ICH had exceeded 160/90 mm Hg at least twice (in accordance with the World Health Organization/International Society of Hypertension statement), 28 or if they were taking antihypertensive medication. Patients not taking antihypertensive medication but with repeated blood pressure measurements exceeding 160/90 mm Hg, and those who had terminated their antihypertensive medication without medical approval were classified as having untreated hypertension. Diabetes was recorded for patients taking oral hypoglycemic agents or insulin. Previous hemorrhagic (ICH and subarachnoid hemorrhage) and ischemic strokes (including transient ischemic attacks) were recorded. Cardiac disease history included previous myocardial infarction, coronary artery disease, heart failure, and atrial fibrillation. Recent heavy drinking was defined as weekly ingestion of at least 300 g of ethanol in the month preceding the stroke. These data were obtained from interviews with patients and/ or their relatives. Alcohol intake data were missing in 9% of patients. The patients' survival during the first 3 months after the onset of ICH was checked from hospital records and death records obtained from the Causes of Death Register maintained by Statistics Finland. Autopsy records were also examined.
Medical Treatment
All patients received standardized medical treatment according to the institutional protocol for acute cerebrovascular diseases. Blood pressure and plasma glucose levels were monitored. The MABP was calculated by adding one-third of the pulse pressure (systolic minus diastolic) to the diastolic pressure. Patients with admission hyperglycemia (plasma glucose > 8 mmol/L or 144 mg/dl) were given short-acting insulin to reach a target level of < 8 mmol/L. Likewise, patients with admission pressure > 180/100 mm Hg (considered MABP > 127 mm Hg), received intravenous antihypertensive drugs (usually labetalol hydrochloride) to reach a target MABP < 120 mm Hg.
Statistical Methods
Data were analyzed with commercially available statistical software (SPSS for Windows, version 12.0.1, SPSS, Inc.). For univariate statistics, conventional statistical tests were used. Univariate association of continuous variables was tested with the Spearman rank correlation coefficients. For life table analysis and the Cox proportional hazards regression model, each patient underwent follow-up until death or for 3 months after ICH. Cumulative survival rates were estimated with the Kaplan-Meier product limit method, and the curves of the different groups were compared with the log-rank test. The Cox proportional hazards model with a forward stepwise regression procedure was used to determine the significance of several variables in predicting RRs with 95% CIs for death. The following variables, known at the beginning of follow-up, were analyzed: age, sex, history of hypertension, previous ischemic stroke, previous hemorrhagic stroke, cardiac disease, diabetes, cancer, hematoma size, location of the hematoma, presence of IVH, warfarin treatment, regular aspirin use, GCS score at admission, current smoking and recent heavy drinking status, plasma glucose level at admission, and blood pressure at admission. The assumption of proportionality was checked. The test for significance was based on changes in log (partial) likelihood. A 2-tailed probability value < 0.05 was considered statistically significant.
Results
The patients' baseline characteristics are shown in Table 1 . Diabetes, cardiac disease, advanced age, and the use of either warfarin or aspirin were significantly more common among the patients who died within 3 months of ICH onset. In addition, there was a significant (p < 0.001) association between hypertensive status and case fatality.
The clinical characteristics are summarized in Table  2 . The patients who died within 3 months had significantly lower GCS scores, larger hematomas, and higher plasma glucose levels and MABPs at admission than those who did not; they were also more likely to have an IVH. There was a significant association between hematoma location and death rate: patients with infratentorial bleeding and those with extension of the putaminal hematoma into the thalamus and/or subcortical white matter showed a higher case fatality rate. Admission glucose levels were higher in those who died within 2 days (mean ± SD, 11.1 ± 4.1 vs 7.6 ± 3.0 mmol/L; p < 0.001) and 3 months (9.5 ± 3.8 vs 7.4 ± 2.9 mmol/L; p < 0.001) than in those who survived. Likewise, admission MABPs were higher in those who died within 2 days (mean ± SD, 137 ± 22 vs 125 ± 21 mm Hg; p < 0.001) and within 3 months (132 ± 21 vs 124 ± 21 mm Hg; p < 0.01) than in those who survived. There was a significant correlation between admission MABP and plasma glucose values (r s = 0.20, p < 0.001) even after the exclusion of patients with diabetes (r s = 0.17, p < 0.01).
The predictors of death in the first 2 days and within 3 months after ICH identified with stepwise Cox regression after adjustment for sex are shown in Tables 3 and  4 . Forty patients (11%) died within 2 days, and 106 died (28%) within 3 months. The significant independent predictors for death within 2 days were hematoma size, low GCS score, and preceding use of warfarin. The predictors for death within 3 months additionally included cardiac disease, IVH, advanced age, and high MABP on admission. A high admission plasma glucose level was not a significant predictor of death either within 2 days or within 3 months. In a separate analysis we replaced plasma glucose and MABP with diabetes and hypertension (grouping treated and untreated individuals together). Diabetes but not hypertension proved to be a significant independent predictor of death within 3 months of ICH (RR 1.61, 95% CI 1.03-2.53; p < 0.05).
Next we analyzed the survival of patients with the highest (75th) quartile of admission MABP (MABP > 139 mm Hg, 104 patients) and plasma glucose (> 8.8 mmol/L, 93 patients). The 3-month survival rates of these patients were significantly lower than those of the patients with lower MABP and glucose at admission (p < 0.01). Twenty-one (20.2%) of 104, and 25 (26.9%) of 93 patients belonging to the highest quartile according to admission MABP and plasma glucose level, respectively, died within 2 days. These patients had substantially larger hematomas compared with the others (p < 0.001). We separately analyzed the 3-month survival of the patients who survived for 2 days or longer. Patients with high admission plasma glucose levels showed significantly (p < 0.01) shorter survival within 3 months (Fig. 1) than the others. Patients with diabetes had a shorter 3-month survival period than nondiabetics (p < 0.001). In contrast, we did not observe a significant difference in survival between those with or without high MABP at admission (p = 0.35) (Fig. 2) .
Medication was given to 184 patients to lower the high blood pressure noted at admission. This treatment was started immediately after admission. The patients who received medical treatment had significantly higher mean MABPs (p < 0.001) than those who did not (mean ± SD, 135 ± 19 vs 118 ± 19 mm Hg). However, we did not observe any significant difference in either the 2-day or the 3-month survival rates between the treated and untreated patients. Nor did the treated patients differ from the untreated ones in initial hematoma volume (25.8 ± 34.2 vs 24.5 ± 31.9 ml). Hematoma size did not show an association with admission MABP either in the whole population or among those who with a history of treated hypertension.
Hematoma volume was associated with admission plasma glucose level. After all patients with diabetes were excluded, the plasma glucose level increased with hematoma volume (r s = 0.195, p < 0.001). Seventy-three nondiabetic patients had admission hyperglycemia (blood glucose > 8 mmol/L). They showed significantly shorter survival despite treatment with short-acting insulin than those with lower admission plasma glucose (p < 0.001).
After patients with diabetes and those who died within the first 2 days were excluded, patients with hyperglycemia at admission still showed a higher 3-month death rate than those without (p < 0.01). Among patients with hyperglycemia, those who survived had smaller hematomas than those who died (13.6 ± 12.2 vs 47.2 ± 44.8 ml; p < 0.001).
Discussion
We found high admission MABP to be an independent predictor of early death without any significant association with admission hematoma volume. On the other hand, a high admission plasma glucose level did not independently predict early death but was significantly associated with the severity of ICH (the larger the hematoma volume, the higher the plasma glucose level at admission). However, previously diagnosed diabetes predicted early death, whereas hypertension did not.
Our finding that admission hyperglycemia is not an independent predictor of early death either in patients with or without diabetes agrees with the conclusion of Capes and colleagues 5 in their meta-analysis of 4 previous studies. Hematoma volume was the main determinant of poor outcome, and admission hyperglycemia associated with the severity of bleeding. In many patients, a high plasma glucose level at admission was probably attributable to a stress reaction caused by the large hematoma. Stress-induced hyperglycemia has previously been shown to predict poor outcome after ischemic stroke and subarachnoid hemorrhage. 5, 11, 15 Subarachnoid hemorrhage has been shown to result in massive sympathetic nervous activation, which could explain the high admission MABP and glucose levels. 19 Acute ICH may also involve activation of the sympathetic nervous system reflecting a stress reaction. Accordingly, the same mechanism may lay behind high admission MABP and glucose among patients with ICH.
In our patient population, a high admission MABP predicted early death, but it was not significantly associated with hematoma volume. It has been reported that elevated blood pressure increases the risk of hematoma growth, 17, 20 and that hematoma growth is an independent risk factor for early death. 8, 12 We did not have systematic hematoma growth data, which could have been used to test whether a high admission MABP actually increased the hematoma growth rate. Furthermore, for moribund patients who died soon after admission, it was not possible to obtain follow-up CT scans. Previous investigations have shown that high blood pressure in the first 48 hours 4, 18, 25, 29 and rapid decline in MABP within 24 hours after presentation 22 predict poor outcome and early death after ICH. However, it has not been demonstrated that acute lowering of blood pressure will result in a better outcome in patients who already have large hematomas at admission.
In our study, 40 patients died in the first 2 days, and 21 of these had had a high MABP at admission. Most of these patients (30/40) had large hematomas at admission, and we believe that some had high MABP due to reflex systemic hypertension resulting from elevated ICP (Cushing reflex). 6 In patients with Cushing reflex, blood pressure is elevated concomitantly with ICP to maintain sufficient perfusion pressure in the brain. If ICP continues to increase, however, the vasomotor center fails, blood pres- (20) 40 (15) 61 (16) * Mean arterial blood pressure is given in mm Hg, PGL is given in mmol/L, and ICH volume in ml. Abbreviations: BP = blood pressure; med = median; PGL = plasma glucose level; vol = volume. † Indicates extension of putaminal hematoma into thalamus and/or subcortical white matter.
sure rapidly declines, and death results within a couple of hours. Therefore, some patients who were already moribund at admission may have presented with low blood pressures, and this could explain why high admission MABP was not associated with hematoma volume. A history of hypertension did not predict poor outcome. In our study, patients with a history of hypertension included patients with both treated and untreated hypertension. Those with untreated hypertension were relatively young, did not have a history of cardiovascular attacks, and ICH was the first severe manifestation of their disease. This agrees well with previous findings. In fact, untreated hypertension has been shown to be highly prevalent in patients with ICH and is a significant risk factor for first hemorrhagic stroke. 30 The fact that patients with untreated hypertension were included in the group of patients with hypertension in our study as well as in a previous study 14 could explain why a history of hypertension was not found to be an independent predictor of death or impaired outcome.
It has been suggested that effective lowering of blood pressure immediately after the onset of ICH may improve outcome, 7 possibly because persistently elevated blood pressure may predispose to hematoma expansion. However, this may not be true in patients who already have large hematomas and therefore very high ICPs. Lowering blood pressure in such patients could further increase ICP and decrease perfusion pressure, which could rapidly promote failure of the vasomotor center and lead to death. We do not know whether rapid lowering of blood pressure is associated with an increased death rate in patients with large hematomas. Patients with small hematomas may benefit from lowering of blood pressure, but this has not been proven in controlled trials. The American guidelines recommend lowering of blood pressure in patients when increased ICP is not suspected (Class IIb, level of evidence C). 3 A low rate of neurological deterioration and hematoma expansion has been reported in patients who undergo aggressive treatment for acute hypertension, 23 yet the 1-month death rate was higher (30%) in those who received treatment compared with those who did not (13%). Accordingly, controlled studies are needed to demonstrate the benefit of aggressive treatment of admission hypertension. We did not observe any significant difference in case fatality rate between those who did or did not receive medical treatment for high admission MABP.
We were able show that diabetes is a predictor of early death after ICH, as has already been suggested by the authors of 2 previous studies. 1, 21 Exactly how diabetes increases the risk of an early death remains unclear. Most of its effect on survival is explained by the severity of bleeding. Although diabetes was found to be a strong predictor of early death in both univariate and multivariate analysis, it was a much stronger predictor in univariate analysis. Animal experiments have shown that hyperglycemia causes brain edema and perihematomal cell death after ICH, 26 and patients with diabetes may also have a higher incidence of infectious and cardiac complications. Unfortunately, because autopsies were not performed in all cases, we were unable to prove the role of such complications in our series. Finally, hyperglycemia correction did not result in better survival of our patients. However, the use of insulin treatment seems reasonable because it could prevent infectious complications, as has been shown to be the case in patients with diabetes after coronary surgery. 13 The strict inclusion criteria and the relatively large and homogeneous patient population are strengths of the present study. We also tried to consider as many of the well-known potential risk factors for early death as possible and adjust for them in our analyses. We did not exclude patients based on hematoma location, and we tested glucose level and blood pressure simultaneously in a multivariate model. However, we did not control for fever, which has also been suggested as a predictor of early death, 25 and we could not systematically investigate the hematoma growth rate. The patients who died before they could be transported to the hospital and those lacking admission plasma glucose values and blood pressure recordings were also excluded, as were those who were admitted to the Department of Neurosurgery for immediate operation. We do not believe that excluding patients who lacked relevant admission data caused any bias because the overall mortality rate of all the 453 patients with ICH was 28.4% compared with 28.0% in the 379 included patients. Patients with large cerebellar and subcortical hematomas who presented with an altered level of consciousness usually underwent surgical treatment. 27 We excluded patients who needed immediate surgery because these patients usually receive postoperative care in intensive care units, where they are prone to the influence of many confounding factors such as ICP monitoring and treatment, sedation, use of mannitol, and infections. Such confounding factors could influence outcome and survival. By excluding surgical cases, we can better assess the natural outcome after conservatively treated ICH.
Conclusions
In conclusion, in our cohort of patients who did not undergo surgery, we found that high blood pressure at admission was an independent risk factor for early death, whereas admission hyperglycemia was not. The latter clearly correlated with several factors reflecting the severity of the hemorrhage. Diabetes but not hypertension predicted early death. Controlled trials are needed to demonstrate whether lowering of high blood pressure and glucose levels during the acute phase after ICH results in a better outcome.
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This study was supported in part by a grant to Dr. Tetri from the Orion Corporation. Fig. 2 . Graph of mortality rate of patients who survived for at least 2 days after ICH according to the presence of hypertension at admission (defined as 75th quartile, MABP > 139 mm Hg). Dotted line indicates patients with hypertension, and solid line indicates those without at admission. There was no significant difference between survival curves (p = 0.35, log-rank test) . Fig. 1 . Graph of mortality rate of patients who survived for at least 2 days after ICH according to the presence of hyperglycemia at admission (defined as 75th quartile, glucose > 8.7 mmol/L). Dotted line indicates patients with hyperglycemia, and solid line indicates those without at admission. There was a significant difference between survival curves (p < 0.01, log-rank test).
